Antibiotic Regimen for Infected Diabetic Foot in Hemodialysis Patients with Suspected Hospital-Acquired Pathogens

Initial Assessment and Antibiotic Selection

The American College of Physicians recommends classifying the severity of infection before selecting antibiotics, with severity levels including mild (cellulitis <2 cm from the wound edge, no systemic signs), moderate (cellulitis >2 cm or deep tissue involvement, no systemic toxicity), or severe (systemic signs such as fever, tachycardia, hypotension) 3, 4
For moderate to severe infections in hemodialysis patients with hospital-acquired exposure, the empirical regimen should be vancomycin plus piperacilina-tazobactam, providing coverage against MRSA, gram-negative bacteria (including Pseudomonas), and anaerobes 1, 2

Vancomycin requires monitoring of therapeutic levels and individualized adjustment in hemodialysis, typically administered after each dialysis session 1

The high risk of MRSA, due to hospital exposure, chronic hemodialysis, and recent hospitalization, justifies broad coverage in these patients 4, 1
Coverage of Pseudomonas is necessary, as hemodialysis patients with hospital-acquired infections are at higher risk of Pseudomonas aeruginosa 4, 1

Obtain deep tissue cultures via biopsy or debridement before initiating antibiotics, and adjust the antibiotic regimen once culture and sensitivity results are available, focusing on virulent species (S. aureus, group A/B streptococci) 1, 2, 3

Administer antibiotics for 2-4 weeks, depending on clinical response, for severe infections, with daily evaluation in hospitalized patients 3, 1

Obtain urgent surgical consultation if there are abscesses with deep formation, extensive necrosis or gangrene, necrotizing fasciitis, crepitus, or severe ischemia 1, 2
Surgical debridement is essential within 24-48 hours, combined with antibiotics, as antibiotics alone often fail without adequate source control 1, 2

Linezolid (600 mg every 12 hours, no renal adjustment necessary) or daptomycin (dose adjusted for hemodialysis) are effective alternatives for MRSA coverage 1, 2
Ertapenem (1 gram every 24 hours, adjusted to 500 mg daily in hemodialysis) can substitute for piperacilina-tazobactam if there are contraindications, although it has less anti-Pseudomonas coverage 1

Do not treat clinically uninfected ulcers with antibiotics to prevent infection or promote healing, as there is no evidence to support this practice and it increases antibiotic resistance 3, 1
Do not use unnecessarily broad empirical coverage for mild infections without risk factors for resistant organisms 4, 1
Do not neglect glucose control, as hyperglycemia impairs both infection eradication and wound healing 1

Evaluate clinical response daily in hospitalized patients, with primary indicators being resolution of local/systemic symptoms and clinical signs of inflammation 3, 1
If there is no improvement after 4 weeks of appropriate therapy, reevaluate for undiagnosed abscess, osteomyelitis, antibiotic resistance, or severe ischemia 1, 2